Research summary, narrative review, 2017

Radiation exposure and thyroid cancer: a review

Iglesias ML, Schmidt A, Ghuzlan AA, Lacroix L, Vathaire F, Chevillard S, et al.. Archives of endocrinology and metabolism. 2017

Read the original paper

In plain language

This review finds thyroid cancer risk rises after thyroid doses above about 50-100 mGy, mainly when exposure occurs in childhood; risk in adults is described as low. It does not study fluoroscopy staff.

At a glance

Type of study
Narrative review
Who was studied
General population, Patients
Summary based on
the full text

What it found

  • Thyroid cancer risk rises significantly after a mean childhood thyroid dose of about 50-100 mGy, with no threshold below which risk can be excluded.

    Key figures: 0.05 to 0.1 Gy (50 to 100mGy)

  • Risk is highest with exposure in early childhood and decreases with age, being low in adults.

    Key figures: fivefold greater risk per Gy before age 4 vs 10-14 years

  • Above the threshold dose range, risk increases linearly with dose up to 20-29 Gy.

    Key figures: Odds ratio (OR): 9.8, 3.2-34.8

  • Minimum latency before radiation-related thyroid cancer appears is 5 to 10 years, with risk peaking at 20-35 years.

    Key figures: 5 to 10 years

  • Radiation-induced papillary thyroid cancers frequently carry gene rearrangements (mostly RET/PTC) rather than point mutations.

    Key figures: 23 of 26 tumours

Limits to keep in mind

Narrative review drawing mainly on atomic bomb, nuclear accident and childhood radiotherapy cohorts; it does not address adult occupational exposure, where the authors state risk is low, and screening intensity may bias apparent incidence.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.